# US 2021/0261667 A1 · Blocking type pd-l1 single-domain camel antibody and application thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0261667 A1
- Document ID: US20210261667A1
- Status: Published application
- Kind: A1
- Application number: 16/970,083
- Filed: 2019-02-14
- Published: 2021-08-26
- Earliest claimed: 2018-02-14
- Assignees: Shanghai Novamab Biopharmaceuticals Co., Ltd.
- Applicants: Shanghai Novamab Biopharmaceuticals Co., Ltd.
- Inventors: Yakun WAN; Min ZHU; Xiaoning SHEN; Junwei GAI
- Web page: https://patentgrep.com/patent/US20210261667A1

## CPC

- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- C12N 15/1037: {Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display}
- A61P 35/00: Antineoplastic agents
- A61K 2039/505: {comprising antibodies}
- C07K 2317/22: from camelids, e.g. camel, llama or dromedary
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/35: Valency
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/567: Framework region [FR]
- C07K 2317/569: Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Provided are a single-domain antibody against human programmed death-ligand 1 (PD-L1) and application thereof. The PD-L1 binding molecule of the present invention can be used for treating and/or preventing, or diagnosing PD-L1 related diseases such as tumors.

## Claims

### Claim at position 1

1-18. (canceled)

### Claim 19

An anti-PD-L1 single-domain antibody, which is a single-domain antibody targeting PD-L1 epitope and has a VHH chain having the following 3 complementarity determining regions or CDRs: CDR1 as shown in SEQ ID No: 5, CDR2 as shown in SEQ ID No: 6, and CDR3 as shown in SEQ ID No: 7.

### Claim 20 (depends on 19)

The anti-PD-L1 single-domain antibody of claim 19, wherein the single-domain antibody comprises monomer, divalent and tetravalent form.

### Claim 21 (depends on 19)

The anti-PD-L1 single-domain antibody of claim 19, wherein the VHH chain comprises 4 framework regions or FRs.

### Claim 22 (depends on 19)

The anti-PD-L1 single-domain antibody of claim 19, wherein the four framework regions are selected from the group consisting of:
(a) FR1 as shown in SEQ ID No: 1, FR2 as shown in SEQ ID No: 2, FR3 as shown in SEQ ID No: 3, and FR4 as shown in SEQ ID No: 4; and
(b) FR1 as shown in SEQ ID No: 10, FR2 as shown in SEQ ID No: 11, FR3 as shown in SEQ ID No: 12, and FR4 as shown in SEQ ID No: 13.

### Claim 23 (depends on 19)

The anti-PD-L1 single-domain antibody of claim 19, wherein the single-domain antibody has a VHH chain whose amino acid sequence is as shown in SEQ ID No: 8 and/or SEQ ID No: 14.

### Claim 24 (depends on 19)

The anti-PD-L1 single-domain antibody of claim 19, which is tetravalent anti-PD-L1 single-domain antibody, which has the following structure:
A-L-P˜P-L-A;
wherein,
element P is a monomer of an anti-PD-L1 single-domain antibody whose VHH chain has the following 3 CDRs: CDR1 as shown in SEQ ID No: 5, CDR2 as shown in SEQ ID No: 6, and CDR3 as shown in SEQ ID No: 7;
element A is a sequence as shown in SEQ ID No: 14;
L represents a linker;
“-” represents a peptide bond; and
“˜” represents a disulfide bond.

### Claim 25 (depends on 19)

The anti-PD-L1 single-domain antibody of claim 19, which is a humanized tetravalent anti-PD-L1 single-domain antibody, which is formed by linking an anti-PD-L1 single-domain antibody as shown in SEQ ID No: 14 and an PD-L1 single-domain antibody as shown in SEQ ID No: 16 with a linker of SEQ ID No: 17.

### Claim 26 (depends on 25)

The anti-PD-L1 single-domain antibody of claim 25, wherein the amino acid sequence of the humanized tetravalent anti-PD-L1 single-domain antibody is shown in SEQ ID No: 18.

### Claim 27 (depends on 19)

The anti-PD-L1 single-domain antibody of claim 19, which is an anti-PD-L1 single-domain antibody which is composed of the VHH amino acid sequence shown in SEQ ID No: 14 fused with human immunoglobulin IgG1 amino acid sequence, and the amino acid sequence of the PD-L1 single-domain antibody is shown in SEQ ID No: 16.

### Claim 28 (depends on 1)

A polynucleotide which encodes an anti-PD-L1 single-domain antibody of claim 1.

### Claim 29 (depends on 28)

An expression vector containing a polynucleotide of claim 28.

### Claim 30 (depends on 1)

A host cell whose genome has been incorporated a polynucleotide that encodes an anti-PD-L1 single-domain antibody of claim 1 or which contains an expression vector containing the polynucleotide.

### Claim 31 (depends on 30)

A method for producing an anti-PD-L1 single-domain antibody, which comprises the steps of:
(a) cultivating the host cell of claim 30 under conditions suitable for the production of a single-domain antibody, thereby obtaining a culture containing the anti-PD-L1 single-domain antibody; and
(b) isolating or recovering the anti-PD-L1 single-domain antibody from the culture.

### Claim 32 (depends on 19)

A conjugate which is prepared by linking a chemical label or a biomarker with an anti-PD-L1 single-domain antibody of claim 19.

### Claim 33 (depends on 19)

A kit comprising an anti-PD-L1 single-domain antibody of claim 19 or a conjugate thereof.

### Claim 34 (depends on 19)

A pharmaceutical composition which comprises an anti-PD-L1 single-domain antibody of claim 19 and one or more pharmaceutically acceptable carriers.
